Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid-Polymer Hybrid Nanoparticles

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2021 Apr 15

PMID 33854311

Citations 13

Authors

Intouch Sakpakdeejaroen

Sukrut Somani

Partha Laskar

Margaret Mullin

Christine Dufes

Affiliations

Soon will be listed here.

Abstract

Background: Plumbagin, a naphthoquinone extracted from the officinal leadwort presenting promising anti-cancer properties, has its therapeutic potential limited by its inability to reach tumors in a specific way at a therapeutic concentration following systemic injection. The purpose of this study is to assess whether a novel tumor-targeted, lipid-polymer hybrid nanoparticle formulation of plumbagin would suppress the growth of B16-F10 melanoma in vitro and in vivo.

Methods: Novel lipid-polymer hybrid nanoparticles entrapping plumbagin and conjugated with transferrin, whose receptors are present in abundance on many cancer cells, have been developed. Their cellular uptake, anti-proliferative and apoptosis efficacy were assessed on various cancer cell lines in vitro. Their therapeutic efficacy was evaluated in vivo after tail vein injection to mice bearing B16-F10 melanoma tumors.

Results: The transferrin-bearing lipid-polymer hybrid nanoparticles loaded with plumbagin resulted in the disappearance of 40% of B16-F10 tumors and regression of 10% of the tumors following intravenous administration. They were well tolerated by the mice.

Conclusion: These therapeutic effects, therefore, make transferrin-bearing lipid-polymer hybrid nanoparticles entrapping plumbagin a highly promising anti-cancer nanomedicine.

Citing Articles

Novel Strategies for Tumor Treatment: Harnessing ROS-Inducing Active Ingredients from Traditional Chinese Medicine Through Multifunctional Nanoformulations.

Zhang Z, Li M, Zhang X, Zhou F Int J Nanomedicine. 2024; 19:9659-9688.

PMID: 39309188 PMC: 11416109. DOI: 10.2147/IJN.S479212.

Pharmacological Features and Therapeutic Implications of Plumbagin in Cancer and Metabolic Disorders: A Narrative Review.

Sharma B, Dhiman C, Hasan G, Shamsi A, Hassan M Nutrients. 2024; 16(17).

PMID: 39275349 PMC: 11397539. DOI: 10.3390/nu16173033.

Transferrin-Modified Triptolide Liposome Targeting Enhances Anti-Hepatocellular Carcinoma Effects.

Zhao X, Yang Y, Su X, Xie Y, Liang Y, Zhou T Biomedicines. 2023; 11(10).

PMID: 37893242 PMC: 10604558. DOI: 10.3390/biomedicines11102869.

Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics.

Gajbhiye K, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V Mol Cancer. 2023; 22(1):160.

PMID: 37784179 PMC: 10546754. DOI: 10.1186/s12943-023-01849-0.

Nanoparticle-Based Treatment Approaches for Skin Cancer: A Systematic Review.

Diaz M, Natarelli N, Aflatooni S, Aleman S, Neelam S, Tran J Curr Oncol. 2023; 30(8):7112-7131.

PMID: 37622997 PMC: 10453819. DOI: 10.3390/curroncol30080516.

References

Daniels T, Bernabeu E, Rodriguez J, Patel S, Kozman M, Chiappetta D . The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2011; 1820(3):291-317. PMC: 3500658. DOI: 10.1016/j.bbagen.2011.07.016. View

Guo L, Zhang H, Wang F, Liu P, Wang Y, Xia G . Targeted multidrug-resistance reversal in tumor based on PEG-PLL-PLGA polymer nano drug delivery system. Int J Nanomedicine. 2015; 10:4535-47. PMC: 4509529. DOI: 10.2147/IJN.S85587. View

Mandala Rayabandla S, Aithal K, Anandam A, Shavi G, Nayanabhirama U, Arumugam K . Preparation, in vitro characterization, pharmacokinetic, and pharmacodynamic evaluation of chitosan-based plumbagin microspheres in mice bearing B16F1 melanoma. Drug Deliv. 2010; 17(3):103-13. DOI: 10.3109/10717540903548447. View

Gao H, Yang Z, Zhang S, Cao S, Shen S, Pang Z . Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 2013; 3:2534. PMC: 3755284. DOI: 10.1038/srep02534. View

Toy R, Peiris P, Ghaghada K, Karathanasis E . Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond). 2013; 9(1):121-34. PMC: 4057606. DOI: 10.2217/nnm.13.191. View

Hsu Y, Cho C, Kuo P, Huang Y, Lin C . Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther. 2006; 318(2):484-94. DOI: 10.1124/jpet.105.098863. View

Ahmad A, Banerjee S, Wang Z, Kong D, Sarkar F . Plumbagin-induced apoptosis of human breast cancer cells is mediated by inactivation of NF-kappaB and Bcl-2. J Cell Biochem. 2008; 105(6):1461-71. DOI: 10.1002/jcb.21966. View

Zhang S, Tang C, Yin C . Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification. Drug Deliv. 2013; 22(2):182-90. DOI: 10.3109/10717544.2013.854849. View

Naresh R, Udupa N, Devi P . Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice. J Pharm Pharmacol. 1996; 48(11):1128-32. DOI: 10.1111/j.2042-7158.1996.tb03907.x. View

10.

Zheng Y, Yu B, Weecharangsan W, Piao L, Darby M, Mao Y . Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int J Pharm. 2010; 390(2):234-41. PMC: 3807850. DOI: 10.1016/j.ijpharm.2010.02.008. View

11.

Ernsting M, Murakami M, Roy A, Li S . Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release. 2013; 172(3):782-94. PMC: 3891171. DOI: 10.1016/j.jconrel.2013.09.013. View

12.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

13.

Bothiraja C, Kapare H, Pawar A, Shaikh K . Development of plumbagin-loaded phospholipid-Tween® 80 mixed micelles: formulation, optimization, effect on breast cancer cells and human blood/serum compatibility testing. Ther Deliv. 2013; 4(10):1247-59. DOI: 10.4155/tde.13.92. View

14.

Fredenberg S, Wahlgren M, Reslow M, Axelsson A . The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems--a review. Int J Pharm. 2011; 415(1-2):34-52. DOI: 10.1016/j.ijpharm.2011.05.049. View

15.

Hadinoto K, Sundaresan A, Cheow W . Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm. 2013; 85(3 Pt A):427-43. DOI: 10.1016/j.ejpb.2013.07.002. View

16.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

17.

Dufes C, Al Robaian M, Somani S . Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther Deliv. 2013; 4(5):629-40. DOI: 10.4155/tde.13.21. View

18.

Duraipandy N, Lakra R, Kunnavakkam Vinjimur S, Samanta D, K P, Kiran M . Caging of plumbagin on silver nanoparticles imparts selectivity and sensitivity to plumbagin for targeted cancer cell apoptosis. Metallomics. 2014; 6(11):2025-33. DOI: 10.1039/c4mt00165f. View

19.

Garg N, Tyagi R, Sharma G, Jain A, Singh B, Jain S . Functionalized Lipid-Polymer Hybrid Nanoparticles Mediated Codelivery of Methotrexate and Aceclofenac: A Synergistic Effect in Breast Cancer with Improved Pharmacokinetics Attributes. Mol Pharm. 2017; 14(6):1883-1897. DOI: 10.1021/acs.molpharmaceut.6b01148. View

20.

Lemarie F, Chang C, Blatchford D, Amor R, Norris G, Tetley L . Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration. Nanomedicine (Lond). 2012; 8(2):181-92. DOI: 10.2217/nnm.12.83. View